GHRP-2 vs Octreotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-2
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Full details →Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →Side-by-Side Comparison
| Aspect | GHRP-2 | Octreotide |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 50 mcg–600 mcg |
| Frequency | 3x daily | 3x daily |
| Cycle Length | 8–12 weeks | 4–24 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to the ghrelin receptor (GHS-R) to stimulate GH release from the pituitary. Also has some direct effects on the hypothalamus. Causes less appetite increase than GHRP-6. | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often stacked with GHRH peptides for enhanced GH release. | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. |
| Administration | Subcutaneous injection on an empty stomach. Can be used at bedtime to enhance natural GH pulse during sleep. | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. |
| Side Effects | Moderate hunger increase, water retention, potential prolactin and cortisol elevation (less than GHRP-6), tingling sensations. | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. |
| Best For |
Key Differences
Unique to GHRP-2:
Unique to Octreotide:
Key Studies
GHRP-2
- On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.
Drug testing and analysis, 2021
- Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.
PloS one, 2016
- Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice.
Peptides, 2014
Octreotide
- Octreotide Scan.
2025
- Octreotide and direct/indirect lung injury.
Research in pharmaceutical sciences, 2025
- Octreotide and Octreotide-derived delivery systems.
Journal of drug targeting, 2023
Ready to Learn More?
Looking for trusted sources?